Chromium supplementation for adjuvant treatment of type 2 diabetes mellitus: Results from a pooled analysis

Abstract

Scope:We conducted a pooled analysis of randomized controlled trials to evaluate the effects of chromium supplementation on clinically relevant metabolic biomarkers in type 2 diabetes mellitus (T2DM) patients. Methods and results: Electronic searches were conducted and the bibliographies of located articles were searched, and 28 studies were suitable for statistical pooling. Endpoints were calculated as weighted mean differences (WMDs) with 95% confidence intervals (CIs) by using fixed-effects or random-effects models. Statistical heterogeneity, publication bias, subgroup analyses, sensitivity analysis and meta-regression assessments were also assessed. Chromium reduced levels of fasting plasma glucose (WMD, −0.99 mmol/L; 95% CI, −1.72 to −0.25; p = 0.008), hemoglobin A1c (WMD, −0.54 %; 95% CI, −0.82 to −0.25; p = 0.0002), triglycerides (WMD, −11.71 mg/dL; 95% CI, −18.38 to −5.04; p = 0.0006). Chromium also increased levels of high-density lipoprotein cholesterol (WMD, 1.73 mg/dL; 95% CI, 0.50 to 2.96; p = 0.006). These results were robust in sensitivity analysis and were not dependent on the chromium dose and duration of supplementation. Subgroup analyses indicated that these notably favorable effects were presented in T2DM subjects ingesting chromium chloride and chromium picolinate formulations. Conclusion: Our pooled analysis suggested that chromium supplementation might be a candidate as an adjunct to pharmacological management in patients with T2DM.

Effects of Chromium Picolinate Supplementation on Cardiometabolic Biomarkers in Patients with Type 2 Diabetes Mellitus: a Randomized Clinical Trial

“…Although chromium supplementation was associated with decrease of FBG levels in diabetic patients [1], in the present study CrPic supplementation failed to affect the blood glucose levels while decreased HOMA-IR values. Considering chemistry and pharmacology of chromium, it was a safe nutrient for supplementation in T2DM [22].…”

“…Type 2 diabetes mellitus (T2DM) remains a serious public health problem, with high rates of morbidity and mortality in low-or middle-income countries [1]. The prevalence of T2DM is increasing at an alarming rate, so that the number of Iranian adults suffering from diabetes was more than four millions in 2011 and has been raised by 35% over the past years [2].…”

An integrative collaborative care model for people with mental illness and physical comorbidities

“…The use of omega-3 s for prevention of cardiovascular events has been controversial however the most recent meta-analysis of 127,477 participants demonstrates lower risk of cardiovascular events including AMI, CHD death, and total CVD death [157] with marine omega-3 supplementation. Coenzyme Q10 may be beneficial in heart failure [158] T2D: Zinc [159], curcumin [160], Coenzyme Q10 [161], probiotics [162,163], and chromium [164] have been demonstrated to have beneficial effects on glycemic control and cardiovascular risk factors in meta-analyses in people with T2D…”

Serum chromium level is increased in Jordanian smokers, decreased in jordanians with prediabetes and type 2 diabetes, but not altered in jordanians with hypertension, with obesity, or with family history of diabetes

“…[9] Very recent pooled analysis study conducted by Huang et al suggested that patients with T2D supplemented chromium picolinate or chromium chloride had lower levels of fasting serum glucose. [10] However, earlier in 2016, Costello et al , in a meta-analysis evaluated the later randomized clinical trials, concluded that there is still little reason to recommend chromium supplements to achieve significant improvements in glycemic control. [11] Besides, oral chromium picolinate was found to improved lipid metabolism in obese rats,[12] and in humans.…”